骨髓增生异常综合征血管新生及抗血管新生治疗研究  

Angiogenesis and anti-angiogenic therapy in myelodysplastic syndromes

作　　者：张翔[1] 叶宝东[1] 周郁鸿[1] 

机构地区：[1]浙江中医药大学附属第一医院,杭州310006

出　　处：《生命科学》2013年第1期78-83,共6页Chinese Bulletin of Life Sciences

基　　金：浙江省高校重中之重学科建设(1506006);中华医学会分子生物学临床应用研究专项资金(CAMB-042010)

摘　　要：骨髓增生异常综合征(myelodysplastic syndromes,MDS)为临床难治的血液系统疾病,骨髓血管新生参与其部分发病机制。目前已对MDS骨髓血管新生调节机制进行了一定的研究,并开展临床试验对各类抗血管新生药物在该病中的治疗作用进行评价,将回顾MDS相关的血管新生及抗血管新生治疗,以开拓MDS临床治疗的思路。Myelodysplastic syndromes（MDS） is a heterogeneous group of diseases with bone marrow failure, clonal proliferation, and high risk transforming to acute myeloid leukaemia, but lack of effective treatments for all patients leads to a difficult problem for clinicians. Angiogenesis plays a part role in its pathogenesis, which forms more microvessel niches for MDS stem cells self-renewal and clonal proliferation, so anti-angiogenic therapy may block the progression of MDS through cutting off interaction between stem cells and microvessel endothelial cells. The mechanism of angiogenesis regulation on MDS has been referred to by many researchers and clinical trials for evaluating effects of anti-angiogenic drugs on MDS are carried out now. Though the results may be disappointing, angiogenesis is still a moving target for treatments and combined therapy consisting of anti-angiogenic drugs may work in further researchs. This review focused on angiogenesis and anti-angiogenic therapy in MDS, hoping that it will broad thinking of clinicians and make a breakthrough in treatments.

关 键 词：骨髓增生异常综合征 血管新生 抗血管新生治疗 

分 类 号：Q463[生物学—生理学] R551.3[医药卫生—血液循环系统疾病]